Compare Vanguard Value Index Fund ETF (VTV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Value Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Value Index Fund ETF trades at $223.92, while State Street SPDR S&P Biotech ETF trades at $159.85. Which is the better fit depends on your goals.
| VTV | XBI | |
|---|---|---|
52-Week High | $227.51 | $169.55 |
52-Week Low | $182.86 | $93.43 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vanguard Value ETF (VTV) trades at $224.64, down 0.8% on the day, with a neutral technical signal overall but bullish moving averages. Recent news highlights its outperformance against growth counterparts in 2026, driven by a rotation into value stocks amid market uncertainty. The ETF offers broad exposure to large-cap value equities with a minimal expense ratio of 0.03%, attracting institutional interest as seen in recent 13F filings.
VTV presents a stable investment opportunity for value-oriented investors seeking diversification and dividend income, with a declared dividend of $1.08 payable in June 2026. Risks include underperformance relative to the S&P 500 over the long term and sensitivity to economic cycles that may dampen value stock appeal.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
